The primary endpoint was met: dalpiciclib plus fulvestrant significantly improved progression-free survival versus placebo plus fulvestrant. A manageable safety profile was observed. The authors findings support dalpiciclib plus fulvestrant as a new treatment option in patients with HR+/HER2- ABC who relapsed/progressed on endocrine therapy. Clinical trial information: NCT03927456.
The authors demonstrated, that Trastuzumab plus endocrine therapy was non-inferior (with decreased toxicities) to trastuzumab plus chemotherapy in patients with hormone receptor-positive and HER2-positive metastatic breast cancer. They conclude, that Trastuzumab plus endocrine therapy could provide a more convenient treatment and allow better treatment tolerance. Clinical trial information: NCT01950182.
The authors conclude that VERONICA did not show an improved CBR (complete response, partial response, and stable disease ≥24 weeks) or progression-free survival with VEN + F, vs F alone, in patients with endocrine- and CDK4/6 inhibitor-refractory LA/MBC. There is an ongoing Biomarker analysis. Clinical trial information: NCT03584009.
The survey showed: Most patients with MBC experienced at least one significant treatment-related side effect. But most patients improved after dosage reduction. This means that innovative dosage-related strategies are warranted to sustain Quality of Life. The authors conclude, that patient-physician discussion in which the patient’s physical attributes and circumstances are periodically assessed may determine the right dose for the patient upon treatment initiation and afterward. Most patients would be open to such discussions.
This study shows, that PD-L1 IC+ immune-inflamed tumors ((PD-L1–expressing immune cells on ≥1% of tumor area) and PD-L1 IC+ BLIA (basal-like immune activated) tumors have the highest cancer immunotherapy sensitivity, and LAR (luminal androgen receptor) tumors may be resistant to cancer immunotherapy. Clinical trial information: NCT02425891.
The study shows, that the combination from famitinib with camrelizumab & nab-paclitaxel had promising antitumor activity as 1st-line therapy for IM subtype advanced TNBC patients. The was a manageable toxicity profile observed. The authors are eagerly awaiting the results from the ongoing randomized controlled trial FUTURE-SUPER (NCT04395989). Clinical trial information: NCT04129996.
The authors demonstrated, that 3 weekly cabazitaxel as 1st-line chemotherapy in HER2 negative metastatic breast cancer does not significantly improve progression free survival compared to weekly paclitaxel. But this combination has a lower risk of peripheral neuropathy with better patient-reported overall health outcomes. Cabazitaxel is safe and well-tolerated for metastatic breast cancer patients: It requires fewer hospital visits. According to the authors, this is an important consideration in the COVID pandemic and beyond. Clinical trial information: NCT03048942.